Like other herpes viruses, human herpes virus (HHV)-6 remains in a latent state after primary infection. Reactivation of infection can occur in immunodeficient situations 1, 2 and causes fever, rash, pneumonitis, hepatis and, in some cases, encephalitis. 1, 3, 4 In in vitro studies, ganciclovir (GCV), foscarnet and cidofovir have demonstrated an inhibitory effect against HHV-6, whereas acyclovir is only marginally effective and should not be used for this indication. 5 Yoshida et al. 5 have determined GCV 50% effective inhibitory concentrations (IC 50 ) in cord blood mononuclear cells to be at least 0.65 and 1.33 mg/ml (dependant on the virus strain). Despite the lack of controlled trials of antiviral treatment, several case reports have demonstrated GCV treatment as prophylactic 6, 7 or curative 1, 8, 9 therapy for HHV-6 infections. We report here the case of a 7-year-old patient, who reactivated HHV-6 virus after bone marrow transplantation (BMT) and was successfully treated with high doses of GCV.
A 7-year-old boy underwent mismatched (9/10) unrelated BMT for relapsed acute lymphoblastic leukaemia. He presented before transplantation with a positive serological status for HHV-6 (immunoglobulin G), negative sero-status for cytomegalovirus (CMV) and herpes simplex virus. The transplant was Epstein-Barr viruspositive, whereas HIV, CMV, HTLV, hepatitis (A, B, C), toxoplasmosis serologic assays were negative. HHV-6 status of the donor was unfortunately not tested. The conditioning regimen included 12 Gy total body irradiation, 12 g/m 2 cytarabine and 140 mg/m 2 melphalan. Cyclosporine (3 mg/kg/day) was introduced as twice daily 2-h infusions from BMT day-1 to prevent graft-versus-host disease (GVHD). Antitlymphocyte globulins were administered before BMT at day-5, day-3 and day-1 (7.5 mg/kg total dose). Antimicrobial prophylactic treatments were started from BMT day þ 1. Immunosuppressive therapy between BMT day þ 1 and þ 13 consisted only of cyclosporine infusions, with a twice weekly therapeutic drug monitoring (TDM), to keep a trough blood concentration level between 80 and 100 ng/ml. 10 A grade II GVHD occurred on day þ 13 post BMT and it was decided to add corticoid therapy and increase cyclosporine doses (to reach trough blood concentration levels of 150 ng/ml). GVHD was rapidly controlled. Engraftment occurred at day þ 17 post BMT and the chimaerism status at day þ 30 was 100% donor. The patient left hospital at 30 days post BMT with oral cyclosporine only to be continued for at least 2 months.
The early post transplant period was uncomplicated, but the patient presented with abnormal fever from day þ 51. He was admitted to the transplant unit with clinical symptoms of encephalitis: persistent high fever, progressive stupor, confusion, amnesia, haemiclonic convulsions. Neurological examination revealed no motor, sensory or cerebellar signs. Intensification of his antimicrobial treatment was started with cotrimoxazole, amphotericin B and valaciclovir before identifying the cause as sepsis. HHV-6 encephalitis infection was diagnosed with detection of viral DNA in cerebrospinal fluid (CSF) by means of polymerase chain reaction (PCR) at day þ 53, whereas results of PCR and serological assays for other herpes viruses were negative.
It was decided to switch the antiviral treatment from valaciclovir to GCV intravenously. First doses of GCV administered were 125 mg (5 mg/kg) twice a day (in a 1-h infusion). GCV plasma concentrations were measured for the first time 4 days after therapy initiation, by using a liquid chromatographic method. GCV plasma levels were 0.24 mg/ml (trough concentration) and 5.07 mg/ml (maximum concentration). These analytical results were then computed with the USC Pack pharmacokinetic software, and a new dosage regimen was forecast by using a Bayesian method to reach target trough concentration levels around 1-2 mg/ml. Therefore, it was decided to increase the doses of GCV to 150 mg three times a day. The duration of each GCV infusion was switched from 1 to 2 h (to get higher trough plasma levels without increasing the peak levels too much). Second plasma trough concentration was measured 5 days after changing the dosage regimen and showed a GCV level of 0.7 mg/ml, so GCV doses were increased to 200 mg three times a day in 2-h infusions, in order to reach a target trough concentration of 1 mg/ml in accordance with the Bayesian predictions. A third trough concentration level measurement showed an increase of plasma GCV level with a concentration of 1.1 mg/ml. The patient's renal function was controlled during the therapy with daily plasma creatinine measurement and the patient presented no adverse effects owing to the 'high dose' GCV regimen. The GCV dosage schedule used for the treatment is summarized in Figure 1 .
The patient improved 10 days after initiation and therapeutic monitoring of GCV treatment, with apyrexia and regression of neurological abnormalities. At 3 months post BMT, the patient was alive and well with normal neurologic examination.
As for many drugs, GCV adult doses (10 mg/kg/day for curative treatment) are most often directly applied in paediatric patients, because of the lack of clinical trials. In vitro IC 50 GCV concentrations for HHV-6 viruses are known to be up to 0.94 mg/ml for HHV-6A and up to 1.58 mg/ml for HHV6-B. 5 Plasma concentration levels have to be much greater than this to get efficient concentrations in the CSF. Moreover, if we do not know which type of HHV-6 is responsible (our virology laboratory does not test the serotypes), we have to target the highest values of GCV plasma concentrations to be sure to be efficient against HHV-6B if necessary. GCV doses commonly used in adults led to insufficient plasma levels (below IC 50 ) in this paediatric patient. TDM, associating clinical symptom and GCV plasma concentration measurements led to rapid improvement in clinical outcome for the patient. In our experience, TDM is of particular interest when the viral infection is severe and when localization of the virus is difficult to reach (as CSF). The manufacturer's recommendations propose a 1-h infusion duration, but the switch to 2 h is justified by the time-dependent profile of GCV as it leads to a higher GCV plasma minimal concentration. High doses of GCV were necessary to improve the patient's clinical outcome, and this dose was increased according to low trough concentration levels of the drug. TDM was helpful in allowing us to use such high doses (24 mg/kg/day) without occurrence of any adverse effects.
Conventional GCV dosage regimens are not suitable in some cases, and particularly in young patients because of the lack of knowledge about the pharmacokinetic paediatric profile. Owing to high kidney function values in children, GCV at conventional doses may be ineffective in severe infectious diseases. According to clinical symptoms, viral PCR results and plasma GCV measurements, the regimen must be adapted to reach concentrations up the value of the IC 50 of the drug. 
